News

Articles

The council voted 19–0 to recommend that FDA authorize booster doses of the Moderna COVID-19 vaccine for certain populations.

FDA Advisory Council Unanimously Supports Moderna COVID-19 Booster EUA

AION Labs will be a first-of-its-kind AI/pharma and computational biology innovation lab aimed at spearheading the adoption of AI technologies and computational science. 

AstraZeneca, Merck KGaA, Pfizer, and Teva Team up with Tech and Investment Leaders to Launch New Biotech Innovation Lab 

Pfizer and BioNTech’s request would make them the first vaccine accessible to individuals under the age of 12.

Pfizer, BioNTech Request EUA for COVID-19 Vaccine in Children Aged 5-11

Takeda will use Selecta Bioscience’s ImmTOR platform to develop gene therapies for lysosomal storage disorders.

Selecta Biosciences and Takeda Announce Gene Therapy Platform Licensing Agreement

Merck’s 11.5 billion acquisition of Acceleron gives them access to their lead therapeutic candidate, sotatercept.

Merck Acquires Acceleron for $11.5 Billion

The FDA has amended the emergency use authorization for the Pfizer-BioNTech COVID-19 vaccine to allow a single booster dose to several high-risk populations.

FDA Authorizes Booster Dose of Pfizer-BioNTech COVID-19 Vaccine for Certain Populations

Moderna’s newest insights include an overall efficacy review, a study on breakthrough infections, and a study on long-term immunity.

Moderna Releases New Clinical Data on COVID-19 Vaccine

Moderna’s new single-dose vaccine will be a booster for both COVID-19 and the flu.

Moderna to Develop Combined COVID-19/Flu Vaccine

After receiving the COVID-19 vaccine from a batch of Moderna vaccines that were suspected to have contaminants, two people in Japan died. Meanwhile, another one million doses have been temporarily suspended in Japan.

Two Dead After Receiving Contaminated Moderna COVID-19 Vaccines & Japan Pulls Another 1-Million Doses From Circulation

Pfizer’s proposed $2.26-billion acquisition of Trillium Therapeutics will add next-generation hematology-targeted immuno-therapeutics to its oncology pipeline.

Top News